Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis

Multiple Sclerosis

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions

Mult Scler.

Elliott C, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Wei W, Belachew S, Arnold DL

doi: 10.1177/1352458518814117.

Multiple Sclerosis

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

Ann Neurol.

Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, Chin P, Belachew S, Kappos L

doi: 10.1002/ana.25313.

Multiple Sclerosis

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study

Brain.

Rocca MA, Sormani MP, Rovaris M, Caputo D, Ghezzi A, Montanari E, Bertolotto A, Laroni A, Bergamaschi R, Martinelli V, Comi G, Filippi M

doi: 10.1093/brain/awx250.

Aging and Cognitive FunctionsMultiple Sclerosis

Clinical Correlations of Brain Lesion Location in Multiple Sclerosis: Voxel-Based Analysis of a Large Clinical Trial Dataset

Brain Topogr.

Altermatt A, Gaetano L, Magon S, Häring DA, Tomic D, Wuerfel J, Radue EW, Kappos L, Sprenger T

doi: 10.1007/s10548-018-0652-9.

Multiple Sclerosis

Identification of Chronic Active Multiple Sclerosis Lesions on 3T MRI

AJNR Am J Neuroradiol.

Absinta M, Sati P, Fechner A, Schindler MK, Nair G, Reich DS

doi: 10.3174/ajnr.A5660.

Multiple Sclerosis

Progression of regional grey matter atrophy in multiple sclerosis

Brain.

Eshaghi A, Marinescu RV, Young AL, Firth NC, Prados F, Jorge Cardoso M, Tur C, De Angelis F, Cawley N, Brownlee WJ, De Stefano N, Laura Stromillo M, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Geurts JJG, Vrenken H, Wottschel V, Leurs CE, Uitdehaag B, Pirpamer L, Enzinger C, Ourselin S, Gandini Wheeler-Kingshott CA, Chard D, Thompson AJ, Barkhof F, Alexander DC, Ciccarelli O; MAGNIMS study group

doi: 10.1093/brain/awy088.

Multiple Sclerosis

Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis

Neurology.

Gaetano L, Häring DA, Radue EW, Mueller-Lenke N, Thakur A, Tomic D, Kappos L, Sprenger T

doi: 10.1212/WNL.

Multiple Sclerosis

Sodium intake and multiple sclerosis activity and progression in BENEFIT

Ann Neurol.

Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM7, Radue EW, Kappos L, Pohl C, Ascherio A

doi: 10.1002/ana.24965.

Multiple Sclerosis

Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study

Lancet Neurol.

Trapp BD, Vignos M, Dudman J, Chang A, Fisher E, Staugaitis SM, Battapady H, Mork S, Ontaneda D, Jones SE, Fox RJ, Chen J, Nakamura K, Rudick RA

doi: 10.1016/S1474-4422

Related content

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study

Clinical Correlations of Brain Lesion Location in Multiple Sclerosis: Voxel-Based Analysis of a Large Clinical Trial Dataset

Identification of Chronic Active Multiple Sclerosis Lesions on 3T MRI

Progression of regional grey matter atrophy in multiple sclerosis

Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis

Sodium intake and multiple sclerosis activity and progression in BENEFIT

Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study